Adicet Bio, Inc.

ACET Healthcare Biotechnology

In the quarter to June 2026, EPS grew 63.4% and free cash flow grew 24.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.57 0.57 −11.09%
Market cap
$48.1M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
4/9
Altman Z
4.96
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.62 7.47 7.66 6.71
Net Debt/EBITDA
3.78 5.00 6.51 5.41
Debt/Equity
0.01 0.00 0.01 0.01
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.96) (3.03) (2.00) (1.86)
Book value per Share
19.17 23.10 13.04 11.18
Free Cash Flow
(22.52) (20.90) (21.53) (20.02)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates